Cargando…
Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power
BACKGROUND: Sample sizes for single-stage phase II clinical trials in the literature are often based on exact (binomial) tests with levels of significance (alpha (α) <5% and power >80%). This is because there is not always a sample size where α and power are exactly equal to 5% and 80%, respec...
Autores principales: | Khan, I, Sarker, S-J, Hackshaw, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504941/ https://www.ncbi.nlm.nih.gov/pubmed/23169334 http://dx.doi.org/10.1038/bjc.2012.444 |
Ejemplares similares
-
Total Syntheses of
Nominal and Actual Prorocentin
por: Zachmann, Raphael J., et al.
Publicado: (2023) -
Exact Power and Sample Size Calculations for the Two One-Sided Tests of Equivalence
por: Shieh, Gwowen
Publicado: (2016) -
Hyperbolic trade-off: The importance of balancing trial and subject sample sizes in neuroimaging
por: Chen, Gang, et al.
Publicado: (2022) -
The power of and: responsible business without trade-offs
por: Freeman, R Edward, et al.
Publicado: (2020) -
Magnetic resonance microscopy of samples with translational symmetry with FOVs smaller than sample size
por: Serša, Igor
Publicado: (2021)